<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        138-186-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RISEK
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OMEPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Gulf Pharmaceutical Industries (Julphar)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gulf Pharmaceutical Industries (Julphar)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Risek </strong>contains the active substance omeprazole. It belongs to a group of medicines called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.&nbsp;</p><p><strong>Risek</strong> is used to treat the following conditions:</p><p><strong><u>In adults</u></strong><strong>:</strong></p><p>-&nbsp; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</p><p>-&nbsp; Ulcers in the upper part of the intestine (duodenal ulcer) or stomach (gastric ulcer).</p><p>-&nbsp; Ulcers which are infected with bacteria called &lsquo;<em>Helicobacter pylori&rsquo;</em>. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p><p>-&nbsp; Ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). <strong>Risek</strong> can also be used to stop ulcers from forming if you are taking NSAIDs.</p><p>-&nbsp; Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</p><p><strong><u>In children</u></strong><strong>: </strong></p><p><strong><em>Children over 1 year of age and &ge; 10 kg </em></strong></p><p>-&nbsp; &lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the gullet (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn. In children, the symptoms of the condition can include the return of stomach contents into the mouth (regurgitation), being sick (vomiting) and poor weight gain.</p><p><strong><em>Children and adolescents over 4 years of age</em></strong></p><p>-&nbsp; Ulcers which are infected with bacteria called &lsquo;<em>Helicobacter pylori&rsquo;</em>. If your child has this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Risek:</strong></p><p>-&nbsp; If you are allergic to omeprazole or any of the other ingredients of this medicine (listed in section 6: &ldquo;Further Information&rdquo;).</p><p>-&nbsp; If you are allergic to medicines containing other proton pump inhibitors (e.g. pantoprazole, lansoprazole, rabeprazole, esomeprazole).</p><p>-&nbsp; If you are taking a medicine containing nelfinavir (used for HIV infection)</p><p>Do not take <strong>Risek</strong> if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking <strong>Risek</strong>.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking <strong>Risek.</strong></p><p><strong>Risek</strong> may hide the symptoms of other diseases. Therefore, if any of the following happen to you before you start taking <strong>Risek</strong> or while you are taking it, talk to your doctor straight away:</p><p>-&nbsp; You lose a lot of weight for no reason and have problems swallowing.</p><p>-&nbsp; You get stomach pain or indigestion.</p><p>-&nbsp; You begin to vomit food or blood.</p><p>-&nbsp; You pass black stools (blood-stained faeces).</p><p>-&nbsp; You experience severe or persistent diarrhoea, as omeprazole has been associated with a small increase in infectious diarrhoea.</p><p>-&nbsp; You have severe liver problems.</p><p>-&nbsp; You have ever had a skin reaction after treatment with a medicine similar to <strong>Risek </strong>that reduces stomach acid.</p><p>-&nbsp; You are due to have a specific blood test (Chromogranin A).</p><p>If you take <strong>Risek</strong> on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.</p><p>Taking a proton pump inhibitor like <strong>Risek</strong>, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with <strong>Risek</strong>. Remember to also mention any other ill effects like pain in your joints.</p><p><strong>Ask a doctor or pharmacist before using this medicine if you are taking a prescription drug. Acid reducers may interact with certain prescription drugs. </strong></p><p><strong>Children</strong></p><p>Some children with chronic illnesses may require long-term treatment although it is not recommended. Do not give this medicine to children under 1 year of age or &lt; 10 kg.</p><p><strong>Other medicines and Risek </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines that you buy without a prescription. This is because <strong>Risek</strong> can affect the way some medicines work and some medicines can have an effect on <strong>Risek</strong>.</p><p>Do not take <strong>Risek</strong> if you are taking a medicine containing <strong>nelfinavir </strong>(used to treat HIV infection).</p><p><u>Tell your doctor or pharmacist if you are taking any of the following medicines: </u></p><p>-&nbsp; Ketoconazole, itraconazole, posaconazole or voriconazole (used to treat infections caused by a fungus)</p><p>-&nbsp; Digoxin (used to treat heart problems)</p><p>-&nbsp; Diazepam (used to treat anxiety, relax muscles or in epilepsy)</p><p>-&nbsp; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking <strong>Risek</strong></p><p>-&nbsp; Medicines that are used to thin your blood, such as warfarin or other vitamin K blockers. Your doctor may need to monitor you when you start or stop taking <strong>Risek</strong></p><p>-&nbsp; Rifampicin (used to treat tuberculosis)</p><p>-&nbsp; Atazanavir (used to treat HIV infection)</p><p>-&nbsp; Tacrolimus (in cases of organ transplantation)</p><p>-&nbsp; St John&rsquo;s wort (<em>Hypericum perforatum</em>) (used to treat mild depression)</p><p>-&nbsp; Cilostazol (used to treat intermittent claudication)</p><p>-&nbsp; Saquinavir (used to treat HIV infection)</p><p>-&nbsp; Clopidogrel (used to prevent blood clots (thrombi))</p><p>-&nbsp; Erlotinib (used to treat cancer)</p><p>-&nbsp; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your <strong>Risek</strong> treatment</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as <strong>Risek</strong> to treat ulcers caused by <em>Helicobacter pylori </em>infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p><strong>Risek with food and drink </strong></p><p>See section 3.</p><p><strong>Pregnancy, breastfeeding and fertility </strong></p><p>If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used. Your doctor will decide whether you can take <strong>Risek</strong> if you are breastfeeding.</p><p><strong>Driving and using machines </strong></p><p><strong>Risek</strong> is not likely to affect your ability to drive or use any tools or machines. Side effects such as dizziness and visual disturbances may occur (see section 4: &ldquo;Possible side effects&rdquo;). If affected, you should not drive or operate machinery.</p><p><strong>Important information about some of the ingredient of risek</strong></p><p><strong>Risek</strong> capsules contain Sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you how many capsules to take and how long to take them for. This will depend on your condition and how old you are.</p><p><strong>The recommended dose is: </strong></p><p><strong><u>Adults</u></strong><strong>:</strong></p><p>To treat symptoms of GORD such as <strong>heartburn and acid regurgitation</strong>:</p><p>-&nbsp; If your doctor has found that your food pipe (gullet) has been slightly damaged, the recommended dose is 20 mg once a day for 4-8 weeks. Your doctor may tell you to take a dose of 40 mg for a further 8 weeks if your gullet has not yet healed.</p><p>-&nbsp; The recommended dose once the gullet has healed is 10 mg once a day.</p><p>-&nbsp; If your gullet has not been damaged, the usual dose is 10 mg once a day.</p><p>To treat <strong>ulcers in the upper part of the intestine </strong>(duodenal ulcer):</p><p>-&nbsp; The recommended dose is 20 mg once a day for 2 weeks. Your doctor may tell you to take the same dose for a further 2 weeks if your ulcer has not yet healed.</p><p>-&nbsp; If the ulcers do not fully heal, the dose can be increased to 40 mg once a day for 4 weeks.</p><p>To treat <strong>ulcers in the stomach </strong>(gastric ulcer):</p><p>-&nbsp; The recommended dose is 20 mg once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your ulcer has not yet healed.</p><p>-&nbsp; If the ulcers do not fully heal, the dose can be increased to 40 mg once a day for 8 weeks.</p><p>To <strong>prevent the duodenal and stomach ulcers </strong>from coming back:</p><p>-&nbsp; The recommended dose is 10 mg or 20 mg once a day. Your doctor may increase the dose to 40 mg once a day.</p><p>To treat duodenal and stomach <strong>ulcers caused by NSAIDs </strong>(Non-Steroidal Anti-Inflammatory Drugs):</p><p>-&nbsp; The recommended dose is 20 mg once a day for 4&ndash;8 weeks.</p><p>To <strong>prevent duodenal and stomach ulcers </strong>if you are taking <strong>NSAIDs: </strong></p><p>-&nbsp; The recommended dose is 20 mg once a day.</p><p>To treat <strong>ulcers caused by <em>Helicobacter pylori </em></strong>infection and to stop them coming back:</p><p>-&nbsp; The recommended dose is 20 mg <strong>Risek</strong> twice a day for one week.</p><p>-&nbsp; Your doctor will also tell you to take two antibiotics among amoxicillin, clarithromycin and metronidazole.</p><p>To treat too much acid in the stomach caused by a <strong>growth in the pancreas (Zollinger-Ellison syndrome)</strong>:</p><p>-&nbsp; The recommended dose is 60 mg daily.</p><p>-&nbsp; Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for.</p><p><strong><u>Use in children and adolescents </u></strong></p><p>To treat symptoms of GORD such as <strong>heartburn and acid regurgitation</strong>:</p><p>-&nbsp; Children over 1 year of age and with a body weight of more than 10 kg may take <strong>Risek</strong>. The dose for children is based on the child&rsquo;s weight and the doctor will decide the correct dose.</p><p>To treat <strong>ulcers caused by <em>Helicobacter pylori </em></strong>infection and to stop them coming back:</p><p>-&nbsp; Children aged over 4 years may take <strong>Risek</strong>. The dose for children is based on the child&rsquo;s weight and the doctor will decide the correct dose.</p><p>-&nbsp; Your doctor will also prescribe two antibiotics called amoxicillin and clarithromycin for your child.</p><p><strong>Taking this medicine </strong></p><p>-&nbsp; It is recommended that you take your capsules in the morning.</p><p>-&nbsp; You can take your capsules with food or on an empty stomach.</p><p>-&nbsp; Swallow your capsules whole with half a glass of water. Do not chew or crush the capsules. This is because the capsules contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</p><p><strong>What to do if you or your child have trouble swallowing the capsules </strong></p><p>-&nbsp; If you or your child have trouble swallowing the capsules:</p><p>&middot;&nbsp; Open the capsules and swallow the contents directly with half a glass of water or put the contents into a glass of still (non-fizzy) water, any acidic fruit juice (e.g. apple, orange or pineapple) or apple sauce.</p><p>&middot;&nbsp; Always stir the mixture just before drinking it (the mixture will not be clear). Then drink the mixture straight away or within 30 minutes.</p><p>&middot;&nbsp; To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.</p><p><strong>If you take more Risek than you should </strong></p><p>If you take more <strong>Risek</strong> than prescribed by your doctor, talk to your doctor or pharmacist straight away.</p><p><strong>If you forget to take Risek </strong></p><p>If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Risek</strong></p><p>Do not stop taking <strong>Risek </strong>without first talking to your doctor or pharmacist.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following rare but serious side effects, stop taking Risek and contact a doctor immediately: </strong></p><p>-&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).</p><p>-&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>-&nbsp; Yellow skin, dark urine and tiredness which can be symptoms of liver problems.</p><p>Other side effects include:</p><p><strong>Common side effects (may affect up to 1 in 10 people) </strong></p><p>-&nbsp; Headache.</p><p>-&nbsp; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).</p><p>-&nbsp; Feeling sick (nausea) or being sick (vomiting).</p><p>-&nbsp; Benign polyps in the stomach.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people) </strong></p><p>-&nbsp; Swelling of the feet and ankles.</p><p>-&nbsp; Disturbed sleep (insomnia).</p><p>-&nbsp; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.</p><p>-&nbsp; Spinning feeling (vertigo).</p><p>-&nbsp; Changes in blood tests that check how the liver is working.</p><p>-&nbsp; Skin rash, lumpy rash (hives) and itchy skin.</p><p>-&nbsp; Generally feeling unwell and lacking energy.</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people) </strong></p><p>-&nbsp; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.</p><p>-&nbsp; Allergic reactions, sometimes very severe, including swelling of the lips, tongue and throat, fever, wheezing.</p><p>-&nbsp; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.</p><p>-&nbsp; Feeling agitated, confused or depressed.</p><p>-&nbsp; Taste changes.</p><p>-&nbsp; Eyesight problems such as blurred vision.</p><p>-&nbsp; Suddenly feeling wheezy or short of breath (bronchospasm).</p><p>-&nbsp; Dry mouth.</p><p>-&nbsp; An inflammation of the inside of the mouth.</p><p>-&nbsp; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.</p><p>-&nbsp; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.</p><p>-&nbsp; Hair loss (alopecia).</p><p>-&nbsp; Skin rash on exposure to sunshine.</p><p>-&nbsp; Joint pains (arthralgia) or muscle pains (myalgia).</p><p>-&nbsp; Severe kidney problems (interstitial nephritis).</p><p>-&nbsp; Increased sweating.</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people) </strong></p><p>-&nbsp; Changes in blood count including agranulocytosis (lack of white blood cells).</p><p>-&nbsp; Aggression.</p><p>-&nbsp; Seeing, feeling or hearing things that are not there (hallucinations).</p><p>-&nbsp; Severe liver problems leading to liver failure and inflammation of the brain.</p><p>-&nbsp; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>-&nbsp; Muscle weakness.</p><p>-&nbsp; Enlarged breasts in men.</p><p><strong>Not known (frequency cannot be estimated from the available data) </strong></p><p>-&nbsp; Inflammation in the gut (leading to diarrhoea).</p><p>-&nbsp; If you are on <strong>Risek</strong> for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>-&nbsp; Rash, possibly with pain in the joints.</p><p>Omeprazole<strong> </strong>may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a <strong>severely </strong>reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medicine at this time.</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><u>To report any side effect(s):</u></strong><strong><u> </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2340</p><p><strong>Reporting Hotline:</strong> 19999</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp; Do not take <strong>Risek</strong> after the expiry date which is stated on the carton and blister.</p><p>-&nbsp; Store below 30&deg;C, in a dry place, protected from light.</p><p>-&nbsp; Do not take<strong> Risek </strong>if you notice any visible sign of deterioration.</p><p>-&nbsp; Medicines should<em> </em>not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Omeprazole. Each capsule contains 10mg, 20mg, or 40mg of Omeprazole.</p><p>The other ingredients Sucrose, starch, mannitol, primojel, sodium lauryl sulfate, hypromellose, talc, methacrylic acid copolymer and HPMC phthalate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Risek 10mg: Packs of 14 capsules (in a plastic bottle).
Risek 20mg: Packs of 7 capsules (in a plastic bottle).
Risek 20mg: Packs of 14 capsules (in a plastic bottle).
Risek 20mg: Packs of 14 capsules (in 2 blisters of 7 capsules each).
Risek 20mg: Packs of 28 capsules (in 4 blisters of 7 capsules each).
Risek 20mg: Packs of 28 capsules (in a plastic bottle).
Risek 40mg: Packs of 14 capsules (in a plastic bottle).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gulf Pharmaceutical Industries &quot; Julphar&quot;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                        20/05/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي <strong>رايسك</strong> على المادة الفعالة أوميبرازول. والتي تنتمي إلى مجموعة من الأدوية تعرف باسم ̓ مثبطات مضخة البروتون̔. تعمل هذه الأدوية على خفض كمية الحمض الذي تنتجه المعدة.</p><p>يستخدم <strong>رايسك</strong> في علاج الحالات الآتية:</p><p><strong><u>البالغون:</u></strong></p><p>-&nbsp; مرض الارتداد المعدي-المريئي. حيث يحدث ارتجاع للحمض من المعدة إلى المريء (هي القناة الواصلة بين الحلق والمعدة) مسببة &nbsp;بذلك شعور بالألم، التهاب وحرقة المعدة.</p><p>-&nbsp; القرحات في الجزء العلوي من الأمعاء (قرحة الإثنى عشر) أو المعدة (قرحة المعدة).</p><p>-&nbsp; القرحات المصحوبة بحدوث عدوى بكتيرية تعرف باسم &quot;هيليكوباكتر بايلوري&quot;. إذا كنت تعاني من هذه الحالة، قد يصف لك طبيبك المعالج أيضاً &nbsp;بعض المضادات الحيوية لعلاج العدوى وللمساعدة على التئام القرحة.</p><p>-&nbsp; قرحات المعدة التي تسببها الأدوية التي تعرف باسم الأدوية غيرالستيرويدية المضادة للالتهابات. كما<strong> </strong>يساعد <strong>رايسك</strong> &nbsp;أيضاً على منع حدوث القرحات إذا كنت تتناول الأدوية&nbsp; غير الستيرودية المضادة للالتهابات.</p><p>-&nbsp; وجود كميات مفرطة من حمض المعدة الناجمة عن وجود ورم في البنكرياس (متلازمة زولينجر-إليسون).</p><p><strong><u>الأطفال:</u></strong></p><p><strong>الأطفال الذين تزيد أعمارهم عن سنة واحدة وتبلغ أوزانهم &ge; 10 كلغم</strong></p><p>-&nbsp; &nbsp;مرض الارتداد المعدي-المريئي، حيث يحدث إرتجاع لحمض المعدة إلى المريء (هي القناة الواصلة &nbsp;بين الحلق والمعدة) مسبباً &nbsp;بذلك شعور بالألم، التهابات وحرقة المعدة. قد تتضمن أعراض هذه الحالة لدى الأطفال ارتداد محتويات المعدة إلى الفم (ارتجاع)، الشعور بالإعياء (تقيؤ) وزيادة طفيفة في الوزن.</p><p><strong>الأطفال والمراهقون بعمر أكبر من 4 سنوات </strong></p><p>القرحات المصحوبة بحدوث عدوى بكتيرية تعرف باسم &quot;هيليكوباكتر بايلوري&quot;. إذا أصيب طفلك بمثل هذه الحالة، قد يصف لك طبيبك المعالج أيضاً بعض المضادات الحيوية لعلاج العدوى وللمساعدة على التئام القرحة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;يجب عدم تناول رايسك في الحالات التالية:</strong></p><p>-&nbsp; إذا كنت تعاني من الحساسية تجاه أوميبرازول أو أياً من المكونات الأخرى في هذا الدواء (المذكورة في البند رقم 6: &quot;معلومات إضافية&quot;).</p><p>-&nbsp; إذا كنت تعاني من الحساسية&nbsp; تجاه الأدوية التي تحتوي على مثبطات مضخات البروتون &nbsp;الأخرى (على سبيل المثال بانتوبرازول، لانسوبرازول، رابيبرازول وإسوميبرازول).</p><p>-&nbsp; إذا كنت تتناول أحد الأدوية التي تحتوي على نيلفينافير (يستخدم لعلاج فيروس نقص المناعة البشرية المكتسبة).</p><p>يجب عليك عدم تناول<strong> رايسك </strong>إذا كان أياً مما ذكر أعلاه ينطبق عليك. يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول <strong>رايسك،</strong> إذا لم تكن متأكداً من ذلك.</p><p><strong>تحذيرات واحتياطات </strong></p><p>يرجى منك التحدث إلى طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل تناول <strong>رايسك.</strong></p><p>قد يعمل <strong>رايسك</strong> على إخفاء الأعراض المصاحبة للأمراض الأخرى. &nbsp;لذلك، يرجى منك التحدث مع طبيبك المعالج على الفور، إذا كان أياً مما يلي ينطبق عليك قبل أن تبدأ بتناول <strong>رايسك</strong> أو أثناء فترة تناوله:</p><p>-&nbsp; فقدان الكثير من الوزن بدون سبب أو تعاني من مشاكل في البلع.</p><p>-&nbsp; ألم في المعدة أو عسر الهضم</p><p>-&nbsp; بدأت في تقيؤ الطعام أو تقيؤ دموي.</p><p>-&nbsp; في حال خروج براز أسود اللون (براز مصحوب بدماء).</p><p>-&nbsp; إسهال&nbsp; شديد أو مستمر، حيث أن العلاج بأوميبرازول قد يصاحبه زيادة طفيفة في الإسهال الناجم عن العدوى.</p><p>-&nbsp; مشاكل شديدة في الكبد.</p><p>-&nbsp; عانيت مسبقاً من تفاعلات جلدية شديدة بعد تلقي العلاج مع الأدوية المماثلة لدواء <strong>رايسك </strong>التي تعمل على تقليل كمية حمض المعدة.</p><p>-&nbsp; الخضوع لإجراء فحوصات الدم معينة (كروموغرانين أ)</p><p>إذا كنت تتناول <strong>رايسك </strong>على مدى طويل (أكثر من سنة واحدة) سوف يضعك طبيبك المعالج تحت المراقبة المنتظمة. كما يجب عليك الإبلاغ عن أية أعراض جديدة وإستثنائية في حال رؤية طبيبك المعالج.</p><p>إن تناول مثبطات مضخات البروتون على سبيل المثال <strong>رايسك</strong>، وبصورة خاصة على مدى فترات طويلة أكثر من سنة واحدة، قد يزيد قليلاً من خطر حدوث كسر في عظم الورك والمعصم أو العمود الفقري.</p><p>يرجى منك إخبار طبيبك &nbsp;المعالج إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول أياً من الكورتيكوستيرويدات (التي قد تزيد من خطر حدوث هشاشة العظام).</p><p>يرجى منك إخبار طبيبك المعالج في أقرب وقت ممكن<strong>، </strong>في حال حدوث طفح جلدي، وبصورة خاصة عند تعرض مناطق من الجلد إلى الشمس، فقد تكون بحاجة إلى التوقف عن تلقي العلاج مع <strong>رايسك. </strong>كما يجب عليك التذكر أيضاً بإخباره حول أية تأثيرات مرضية على سبيل المثال ألم في المفاصل.</p><p><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه قبل استخدام هذا الدواء، اذا كنت تتناول أي أي دواء يصرف بموجب وصفة طبية. حيث أن الأدوية التي تعمل على تقليل كمية حامض المعدة قد تتفاعل مع هذه االدواء.</strong></p><p><strong>الأطفال</strong></p><p>قد يحتاج بعض الأطفال الذين يعانون من اضطرابات مزمنة إلى علاج طويل المدى، على الرغم من ذلك لا يوصى به. يجب عدم إعطاء هذا الدواء للأطفال بعمر أقل من سنة واحدة أو تبلغ أوزانهم &lt; 10 كلغم.</p><p><strong>تناول الأدوية الأخرى بالتزامن مع رايسك</strong></p><p>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل معه إذا كنت تتناول، أو تناولت مؤخراً، أو قد تتناول أية أدوية أخرى. بما في ذلك الأدوية التي تصرف بدون وصفة طبية. حيث أن <strong>رايسك</strong> قد يؤثر على آلية عمل بعض الأدوية، كما أن بعض الأدوية قد يكون لها تأثيرعلى مفعول<strong> رايسك.</strong></p><p>يجب عدم تناول <strong>رايسك</strong> إذا كنت تتناول أحد الأدوية التي تحتوي على <strong>نلفينافير</strong> (يستخدم لعلاج فيروس نقص المناعة البشرية المكتسبة).</p><p><u>يجب عليك إخبار الطبيب المعالج، أو الصيدلي الذي تتعامل معه إذا كنت تتناول أي من الأدوية التالية:</u></p><p>-&nbsp; كيتوكونازول، إتراكونازول، بوزاكونازول أو فوريكونازول (يستخدم لعلاج العدوى التي تسببها الفطريات)</p><p>-&nbsp; ديجوكسن (يستخدم لعلاج مشاكل القلب)</p><p>-&nbsp; ديازيبام (يستخدم لعلاج القلق، مرخي للعضلات أو لعلاج نوبات الصرع)</p><p>-&nbsp; فينيتوين (يستخدم لعلاج نوبات الصرع). إذا كنت تتناول فينيتوين، سوف يحتاج طبيبك المعالج &nbsp;لمتابعة حالتك &nbsp;الصحية عند البدء أو التوقف عن تناول <strong>رايسك</strong>.</p><p>-&nbsp; الأدوية التي تستخدم لترقيق الدم، على سبيل المثال وارفارين أو غالقات مستقبلات فيتامين ك الأخرى. قد يحتاج طبيبك المعالج إلى مراقبة حالتك الصحية عند البدء أو التوقف عن تناول <strong>رايسك</strong></p><p>-&nbsp; ريفامبيسين (يستخدم لعلاج السل)</p><p>-&nbsp; أتازانافير (يستخدم لعلاج فيروس نقص المناعة البشرية المكتسبة)</p><p>-&nbsp; تاكروليمس (يستخدم في عمليات زرع الأعضاء)</p><p>-&nbsp; عشبة ست جونز ورت (هايبريكم بيرفوراتيم) (تستخدم لعلاج حالات الاكتئاب الطفيفة)</p><p>-&nbsp; سيلوستازول (يستخدم لعلاج حالات العرج المتقطع)</p><p>-&nbsp; ساكوينافير (يستخدم لعلاج عدوى فيروس نقص المناعة البشرية المكتسبة)</p><p>-&nbsp; كلوبيدوجريل (يستخدم لمنع حدوث تجلطات في الدم)</p><p>-&nbsp; إيرلوتينيب (يستخدم لعلاج السرطان)</p><p>-&nbsp; ميثوتريكسات (دواء كيميائي يستخدم بجرعات كبيرة لعلاج السرطان)- إذا كنت تتناول جرعات كبيرة من ميثوتريكسات، قد يقوم طبيبك المعالج بإيقاف العلاج مع <strong>رايسك</strong> بصورة مؤقتة.</p><p>&nbsp;إذا وصف لك طبيبك المعالج مضادات حيوية على سبيل المثال أموكسيسيلين وكلاريثرومايسين بالتزامن مع <strong>رايسك</strong> لعلاج القرحة الناجمة عن العدوى بهيليكوباكتر بايلوري، &nbsp;فمن الضروري أن تخبر طبيبك المعالج عن أية أدوية أخرى تتناولها</p><p><strong>تناول رايسك مع الطعام والشراب</strong></p><p>انظر البند رقم 3.</p><p><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong></p><p>يرجى منك استشارة &nbsp;طبيبك المعالج أو الصيدلي الذي تتعاملين معه للحصول على النصيحة قبل تناول هذا الدواء، إذا كنت حاملاً أو ترضعين طفلك رضاعة طبيعية، تعتقدين أنك حاملاً أو تخططين لإنجاب طفلاً.</p><p>يفرز أوميبرازول في حليب الثدي ولكن ليس من المحتمل أن يؤثر ذلك على الطفل عند تناول <strong>رايسك</strong> ضمن حدود الجرعات العلاجية. سوف يقرر طبيبك المعالج ما إذا كان بإمكانك تناول &nbsp;<strong>رايسك</strong> إذا كنت ترضعين طفلك رضاعة طبيعية.</p><p><strong>&nbsp;القيادة وتشغيل الآلات&nbsp; </strong></p><p>&nbsp;ليس من المحتمل أن يؤثر <strong>رايسك</strong> على قدرتك على القيادة أو استخدام الأدوات والآلات.&nbsp;</p><p>&nbsp;قد تحدث بعض التأثيرات الجانبية مثل الدوخة واضطربات الرؤية (انظر البند رقم 4: التأثيرات الجانبية المحتمل حدوثها). &nbsp;يجب عليك عدم القيادة أو تشغيل الآلات، في حال حدوث هذه التأثيرات الجانبية.</p><p><strong>معلومات هامة حول بعض مكونات رايسك</strong></p><p>تحتوي كبسولات<strong> رايسك </strong>على السكروز.<strong>&nbsp; </strong>يرجى منك استشارة طبيبك المعالج قبل تناول هذا الدواء إذا قد أخبرك<strong> </strong>أنك تعاني من مشكلة تتمثل في عدم القدرة على تحمل بعض أنواع السكر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب علي دائماً تناول هذا الدواء تبعاً لتعليمات طبيبك المعالج &nbsp;أو الصيدلي الذي تتعامل معه بدقة. يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه ما لم تكن متاكداً من كيفية تناول هذا الدواء.</p><p>سوف يخبرك طبيبك المعالج بعدد الكبسولات التي يجب عليك تناولها ومدة العلاج، اعتماداً على حالتك الصحية وعمرك.</p><p><strong>الجرعة الموصى بها:</strong></p><p><strong><u>البالغون:</u></strong></p><p>لعلاج أعراض أمراض الارتداد المعدي-المريئي على سبيل المثال <strong>حرقة المعدة</strong> <strong>وارتجاع الحمض</strong>:</p><p>-&nbsp; إذا لا حظ طبيبك المعالج &nbsp;حدوث تضرر بسيط في القناة الناقلة للطعام (المريء) ، فإن الجرعة الموصى بها هي 20ملغم &nbsp;مرة واحدة يومياً لمدة 4-8 أسابيع.&nbsp; في حال عدم &nbsp;شفاء المريء قد يخبرك طبيبك المعالج أن تتناول جرعة مقدارها 40 ملغم لمدة 8 أسابيع إضافية.</p><p>-&nbsp; الجرعة الموصى بها في حال شفاء المريء هي 10ملغم مرة واحدة يومياً.</p><p>-&nbsp; في حالة عدم وجود تضرر في المرئ، يكون مقدار الجرعة الاعتيادية هي 10 ملغم مرة واحدة يومياً.</p><p>لعلاج<strong> قرحات الجزء العلوي من الأمعاء </strong>(قرحة الإثنى عشر):<strong>&nbsp; </strong></p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 20 ملغم مرة واحدة يومياً لمدة أسبوعين. قد يخبرك طبيبك المعالج أن تتناول نفس الجرعة لمدة أسبوعين إضافيين إذا لم تشفى القرحة التي تعاني منها بعد.</p><p>-&nbsp; إذا لم يتم الشفاء الكامل للقرحة، يمكن زيادة الجرعة إلى 40 ملغم مرة واحدة يومياً لمدة 4 أسابيع.</p><p>&nbsp;لعلاج <strong>قرحات المعدة:</strong></p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 20 ملغم مرة واحدة يومياً لمدة 4 أسابيع. قد يخبرك طبيبك المعالج بأن تتناول نفس الجرعة&nbsp; لمدة 4 أسابيع إضافية إذا لم&nbsp; تشفى القرحة التي تعاني منها بعد.</p><p>-&nbsp; إذا لم تشفى القرحة بصورة تامة، يمكن زيادة الجرعة إلى 40 ملغم مرة واحدة يومياً لمدة 8 أسابيع.</p><p><strong>&nbsp;لمنع</strong> <strong>تكرار حدوث</strong> <strong>قرحات المعدة والإثنى عشر</strong>:</p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 10ملغم أو 20 ملغم مرة واحدة يومياً. قد يقوم طبيبك المعالج بزيادة مقدار الجرعة إلى 40 ملغم مرة واحدة يومياً.</p><p>&nbsp;لعلاج قرحات المعدة والإثنى عشر <strong>الناجمة عن الأدوية غير الستيرويدية المضادة للالتهابات</strong>:</p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 20 ملغم مرة واحدة يومياً لمدة 4-8 أسابيع.</p><p><strong>للوقاية من قرحات المعدة والإثنى عشر</strong><strong> </strong>إذا<strong> </strong>كنت تتناول<strong> الأدوية غير الستيرويدية المضادة للالتهابات:</strong></p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 20 ملغم مرة واحدة يومياً.</p><p>-&nbsp; للعلاج من <strong>القرحات الناجمة</strong> <strong>عن العدوى بهيليكوباكتر بايلوري </strong>ومنع معاودة حدوثها مرة أخرى:</p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 20 ملغم &nbsp;من <strong>رايسك</strong> مرتان يومياً لمدة أسبوع واحد.</p><p>-&nbsp; كما سيخبرك طبيبك المعالج &nbsp;أن تتناول نوعين من المضادات الحيوية تتضمن الأموكسيسلين، كلاريثرومايسين وميترونيدازول.</p><p>لعلاج الزيادة في كمية الحمض الناجم <strong>عن وجود ورم في البنكرياس (متلازمة زولينجر-اليسون):</strong></p><p>-&nbsp; يبلغ مقدار الجرعة الموصى بها 60 ملغم يومياً.</p><p>-&nbsp; سيقوم طبيبك المعالج بتعديل مقدار الجرعة اعتماداً على مدى احتياجاتك كما أنه سوف يقرر ما المدة العلاجية &nbsp;التي تحتاجها لتناول هذا الدواء.</p><p><strong><u>الأطفال والمراهقون:</u></strong></p><p>لعلاج أعراض مرض الارتداد المعدي-المريئي على سبيل المثال <strong>حرقة الفؤاد وإرتجاع الحمض:</strong></p><p>-&nbsp; قد يتناول الأطفال بعمر أكبر من سنة واحدة وتصل أوزانهم أكثر من 10 كلغم &nbsp;<strong>رايسك</strong>. يتم تحديد مقدار الجرعة المخصصة للأطفال اعتماداً على وزن الطفل وسيقرر الطبيب المعالج المقدار الصحيح من الجرعة.</p><p>لعلاج القرحات <strong>الناجمة عن العدوى بهيليكوباكتر بايلوري</strong> ومنع معاودة حدوثها مرة أخرى:</p><p>-&nbsp; الأطفال بعمر أكبر من 4 سنوات قد يتناولون<strong> رايسك</strong>. يعتمد مقدار الجرعة لدى الأطفال على وزن الطفل وسوف يقرر الطبيب المعالج المقدار الصحيح من الجرعة.</p><p>-&nbsp; كما سيصف الطبيب المعالج لطفلك نوعين من المضادات الحيوية المعروفة باسم أموكسيسللين وكلاريثرومايسين.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><strong>حول تناول هذا الدواء</strong></p><p>-&nbsp; يوصى بتناول الكبسولات في الصباح</p><p>-&nbsp; يمكن تناول الكبسولات مع الطعام أو على معدة خاوية.</p><p>-&nbsp; يجب ابتلاع الكبسولات كاملة مع نصف كوب من الماء. يجب عدم مضغ أو سحق &nbsp;الكبسولات. حيث أن الكبسولات تحتوي على حبيبات تم تغليفها&nbsp; للمحافظة على الدواء من التكسر نتيجة تأثير حمض المعدة. لذلك من المهم الحفاظ على هذه الحبيبات من التلف.</p><p><strong>ما عليك القيام به إذا كنت تعاني</strong> <strong>أو يعاني طفلك من مشكلة في ابتلاع الكبسولات </strong></p><p>-&nbsp; إذا كنت تعاني أو يعاني طفلك من مشكلة في ابتلاع الكبسولات:</p><p>&middot;&nbsp; قم بفتح الكبسولات وقم بابتلاع محتويات الكبسولة مباشرة بنصف كوب من الماء أو إفراغ محتوياتها في نصف كوب من مياه غير غازية، أي عصير من الفواكه الحمضية (على سبيل المثال. تفاح،&nbsp; برتقال، أو أناناس) أومع عجينة التفاح.</p><p>&middot;&nbsp; دائماً حرك الخليط قبل تناوله ( سوف يكون الخليط غير صاف ). ثم قم بشرب الخليط على الفور أو في خلال 30 دقيقة.</p><p>&middot;&nbsp; للتاكد من شرب الدواء كاملاً. قم بشطف الكوب جيداً بنصف كوب من الماء ثم قم بشربه. تحتوي الحبيبات الصلبة التي تم إفراغها في الماء على الدواء &ndash; لذلك لا تقم بمضغها أو سحقها.</p><p><strong>إذا تناولت رايسك بجرعة أكبر مما يجب عليها تناولها</strong></p><p>يرجى منك التحدث مع طبيبك المعالج أو الصيدلي الذي تتعامل معه على الفور، إذا تناولت <strong>رايسك</strong> بجرعة أكبر من التي وصفها لك طبيبك المعالج.</p><p><strong>إذا سهوت عن تناول رايسك</strong></p><p>إذا سهوت عن تناول إحدى الجرعات من <strong>رايسك، </strong>فيجب عليك تناولها في أقرب وقت ممكن حال تذكرها. على الرغم من ذلك، يرجى منك التخطي عن الجرعة التي قد سهوت عن تناولها في حال اقتراب موعد تناول الجرعة التالية. يجب عليك عدم مضاعفة الجرعة لتعويض الجرعة التي قد سهوت عنها.</p><p><strong>إذا توقفت عن تناول رايسك</strong></p><p>يجب عدم التوقف عن تناول <strong>رايسك </strong>دون استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه أولاً.</p><p><strong>يرجى منك استشارة طبيبك المعالج أو الصيدلي الذي تتعامل معه، إذا كان لديك أية أسئلة إضافية حول استعمال هذا الدواء.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>كما هو عليه الحال مع جميع الأدوية، قد يتسبب هذا الدواء في حدوث تأثيرات جانبية، على الرغم من أنها قد لا تحدث لكل شخص.</p><p><strong>يرجى منك التوقف عن تناول رايسك واتصل بطبيبك المعالج على الفور، إذا لاحظت حدوث أياً من التأثيرات الجانبية النادرة التالية ولكنها تعد خطيرة:</strong></p><p>-&nbsp; أزيز مفاجئ، تورم في الشفتين، اللسان، الحلق، أو الجسم، طفح جلدي، إغماء أو صعوبة في البلع ( تفاعلات تحسسية شديدة).</p><p>-&nbsp; إحمرار الجلد مع ظهور تقرحات جلدية أو تقشر في الجلد. قد يظهر أيضاً تقرحات شديدة ونزيف في الشفتين، العينين، الفم، الأنف والأعضاء التناسلية. قد تكون هذه أعراض &quot;متلازمة ستيفنز-جونسون&quot; أو &quot;انحلال البشرة السمي التنخري&quot;.</p><p>-&nbsp; اصفرار الجلد، بول داكن اللون وشعور بالتعب، قد يكون ذلك أعراض وجود مشاكل في الكبد.</p><p>تتضمن التأثيرات الجانبية الأخرى على :</p><p><strong>التأثيرات الجانبية الشائعة (قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص)</strong></p><p>-&nbsp; صداع.</p><p>-&nbsp; تأثيرات على المعدة أو القناة الهضمية: إسهال، ألم في المعدة، إمساك، وريح (انتفاخ).</p><p>-&nbsp; شعور بالإعياء (غثيان) أو توعك (تقيؤ).</p><p>-&nbsp; أورام حميدة في المعدة</p><p><strong>التأثيرات الجانبية الغير شائعة (قد تصيب ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><p>-&nbsp; تورم القدمين والكاحلين.</p><p>-&nbsp; اضطراب في النوم (أرق).</p><p>-&nbsp; دوخة، إحساس بالوخز &quot; يشبه الوخز بالدبابيس والإبر&quot;، شعور بالنعاس.</p><p>-&nbsp; شعور بالدوار.</p><p>-&nbsp; تغيرات في فحوصات الدم التي تكشف عن مدى كفاءة وظيفة الكبد.</p><p>-&nbsp; طفح جلدي، وطفح متكتل (طفح جلدي شبيه بخلايا النحل)، وحكة في الجلد.</p><p><strong>-&nbsp; </strong>شعور عام بالتعب وفقدان النشاط<strong> </strong></p><p><strong>التأثيرات الجانبية النادرة (قد تصيب ما يصل إلى شخص واحد لكل 1000 شخص)</strong></p><p>-&nbsp; اضطرابات في الدم على سبيل المثال نقص تعداد خلايا الدم البيضاء أو الصفائح الدموية. قد تسبب هذه الاضطرابات شعور بالضعف، ظهور كدمات أواحتمال حدوث العدوى بشكل كبير</p><p>-&nbsp; تفاعلات تحسسية، &nbsp;في بعض الأحيان تكون حادة جداً، بما في ذلك تورم الشفتين، اللسان والحلق، حمى وأزيز.</p><p>-&nbsp; انخفاض مستويات الصوديوم في الدم. مما قد يسبب ضعف، توعك (تقيؤ) وتقلصات.</p><p>-&nbsp; الإنفعال، ارتباك والاكتئاب.</p><p>-&nbsp; اضطرابات في حاسة التذوق.</p><p>-&nbsp; مشاكل في الرؤية على سبيل المثال عدم وضوح الرؤية</p><p>-&nbsp; شعور مفاجئ بالأزيز أو بضيق في التنفس (تقلص في الشعب الهوائية).</p><p>-&nbsp; جفاف الفم.</p><p>-&nbsp; التهاب داخل الفم.</p><p>-&nbsp; الإصابة بعدوى تعرف باسم &quot;القلاع&quot; الناجمة عن الفطريات والتي يمكن أن تؤثر على القناة الهضمية.</p><p>-&nbsp; مشاكل في الكبد، بما في ذلك اليرقان الذي قد يسبب اصفرار في الجلد، بول داكن اللون وشعور بالتعب.</p><p>-&nbsp; تساقط الشعر (صلع).</p><p>-&nbsp; طفح جلدي عند التعرض لأشعة الشمس.</p><p>-&nbsp; ألم في المفاصل أو العضلات.</p><p>-&nbsp; مشاكل شديدة في الكلى (التهاب الكلية الخلالي).</p><p>-&nbsp; زيادة التعرق.</p><p><strong>&nbsp; &nbsp;التأثيرات الجانبية النادرة جداً (قد تصيب ما يصل إلى شخص واحد من كل 10000 شخص)</strong></p><p>-&nbsp; تغيرات في تعداد خلايا الدم بما في ذلك ندرة المحببات (نقص كريات الدم البيضاء).</p><p>-&nbsp; الشعور بالعدوانية.</p><p>-&nbsp; رؤية، &nbsp;شعور أو سماع أشياء ليس لها وجود (هلوسة).</p><p>-&nbsp; اضطرابات شديدة في الكبد قد تؤدي إلى فشل كبدي أو التهاب في الدماغ.</p><p>-&nbsp; ظهور طفح جلدي شديد أو تقرحات جلدية أو تقشر في الجلد بصورة مفاجئة. وهذا قد يكون مصحوباً بحمى شديدة وآلام في المفاصل (حمامي متعددة الأشكال، متلازمة ستيفنز-جونسون، وانحلال البشرة السمي التنخري).</p><p>-&nbsp; ضعف&nbsp; العضلات.</p><p>-&nbsp; تضخم الثدي لدى الذكور.</p><p><strong>غير معروفة (لا يمكن تقدير معدل تكرار حدوثها من البيانات المتاحة)</strong></p><p>-&nbsp; التهاب في القناة الهضمية (يؤدي إلى حدوث إسهال)</p><p>-&nbsp; إذا كنت تتناول <strong>رايسك</strong> لأكثر من ثلاثة أشهر، فمن الممكن أن يحدث انخفاض لمستويات المغنيسيوم في الدم. ويمكن ملاحظة&nbsp; انخفاض مستويات المغنيسيوم في الدم، متمثلة في الشعور بالتعب، تقلص العضلات اللاإرادية، توهان، تشنجات، دوخة أو زيادة معدل نبضات القلب. يرجى منك إخبار طبيبك المعالج على الفور في حال ظهور أياً من هذه الأعراض. إن انخفاض مستويات المغنيسيوم في الدم قد يؤدي أيضاً إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك المعالج إجراء فحوصات للدم بصورة منتظمة وذلك لمراقبة مستويات المغنيسيوم.</p><p>-&nbsp; طفح جلدي، ومن المحتمل أن يكون مصحوباً بألم في المفاصل.</p><p>قد يؤثر أوميبرازول في حالات نادرة جداً على خلايا الدم البيضاء مما قد يسبب ضعف المناعة. إذا كنت تعاني من عدوى مصحوبة بأعراض مثل الحمى مع تدهورعام <strong>وشديد</strong> في حالتك الصحية أو كنت تعاني من حمى مصحوبة بأعراض العدوى الموضعية على سبيل المثال ألم في الرقبة، الحلق أو الفم أو صعوبة في التبول، يجب عليك استشارة طبيبك المعالج في أسرع وقت ممكن، حيث يكون بالإمكان إجراء فحص الدم لاستبعاد حدوث نقص في تعداد خلايا الدم البيضاء (ندرة المحببات). فيعد ذلك أمراً مهماً، لتوفير لك المعلومات حول الدواء الخاص بك في هذا الوقت.</p><p><strong>يرجى منك إخبار طبيبك المعالج أو الصيدلي الذي تتعامل &nbsp;معه، في حال زيادة حدة التأثيرات الجانبية أو إذا لاحظت حدوث تأثيرات جانبية أخرى لم تذكر في هذه النشرة.</strong></p><p><strong><u>للإبلاغ عن حدوث أية تأثيرات جانبية:</u></strong></p><p><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p><strong>رقم الفاكس:&nbsp;&nbsp; 7662-205-11-966+</strong></p><p><strong>يرجى الاتصال بالمركز الوطني للتيقظ والسلامة الدوائية على: 2038222-11-966+، وصلة هاتف:2340-2356-2317</strong></p><p><strong>الخط الساخن: 19999</strong></p><p><strong>البريد الإلكتروني:&nbsp; </strong><strong>npc.drug@sfda.gov.sa</strong></p><p><strong>الموقع الإلكتروني: </strong><strong>www.sfda.gov.sa/npc</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp; يحفظ هذا الدواء في مكان آمن بعيد عن مرأى ومتناول الأطفال.</p><p>-&nbsp; يجب عدم تناول <strong>رايسك</strong> بعد تاريخ انتهاء الصلاحية المذكور على العبوة والشريط.</p><p>-&nbsp; يحفظ في درجة حرارة أقل من 30&ordm;م، في مكان جاف، بعيداً عن الضوء.</p><p>- يجب عدم تناول <strong>رايسك</strong> إذا لاحظت وجود علامات تلف واضحة.</p><p>-&nbsp; يجب عدم التخلص من الأدوية عبر المياه المبتذلة (مياه الصرف الصحي) أو النفايات المنزلية. اسأل الصيدلي الذي تتعامل معه عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي أوميبرازول. تحتوي كل كبسولة على&nbsp; 10ملغم، 20ملغم، أو 40 ملغم من أوميبرازول.</p><p>المكونات الأخرى: سكروز، نشا، مانيتول، بريموجيل، كبريتات لوريل الصوديوم، هيبروميللوز، تلك، كوبوليمر حامض مثاكريلك، وفثالات إتش بي إم سي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            رايسك 10  ملغم: عبوة تحتوي على 14 كبسولة (في عبوة بلاستيكية).
رايسك 20  ملغم: عبوة تحتوي على 7 كبسولات (في عبوة بلاستيكية).
رايسك 20  ملغم: عبوة تحتوي على 14 كبسولة (في عبوة بلاستيكية).
رايسك 20  ملغم: عبوة تحتوي على 14 كبسولة (في شريطين، يحتوي كل منهما على 7 كبسولات).
رايسك 20  ملغم: عبوة تحتوي على 28 كبسولة (في 4 أشرطة، يحتوي كل منها على 7 كبسولات).
رايسك 20  ملغم: عبوة تحتوي على 28 كبسولة (في عبوة بلاستيكية).
رايسك 40 ملغم: عبوة تحتوي على 14 كبسولة (في عبوة بلاستيكية).

        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&quot;الخليج للصناعات الدوائية &quot; جلفار</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            20-05-2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Risek 10mg Hard Gelatine Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains:
Item No.	Material Name	Scale (mg/Capsule)
		
	Active Ingredient: 	
A.		Omeprazole 	10.00
	Use: Omeprazole Pellets	117.00 *
		
	Composition of Omeprazole Pellets:	
1.		Omeprazole 	10.000
2.		Sucrose and starch neutral microgranules 	88.500 *
3.		Mannitol 	8.350
4.		Primojel 	0.650
5.		Hydroxypropyl methyl cellulose phthalate 	3.300
6.		Sodium lauryl sulphate 	0.300
7.		Hypromellose 	3.000
8.		Talc fine powder 	0.100
9.		Methacrylic acid copolymer 	3.300
10.		Acetone **	q.s. 
11.		Ethanol 95% **	q.s. 
		
B.		Empty hard gelatine capsule shell ***	1 No.
	Size 2	
	Cap: Green opaque 	
	Body: Amethyst opaque	

* To adjust the claim, the weight of Omeprazole Pellets per capsule may vary.
** Evaporates during manufacturing process and do not appear in the final product.
***Composition of capsule shell:  Gelatine, Titanium Dioxide, erythrosine, brilliant blue (E133), D&C yellow 10, Patent blue. 

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatine Capsules (containing delayed release granules)
Description: Size 2, locked capsule containing off-white to light darkish beige micro-granules.
Marking: Cap: printed ‘Julphar’ radial, in black 
                Body: printed ‘10’ radial, in black.
Colour: Cap: Green opaque 
            Body: Amethyst opaque. 





            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Risek</strong> capsules are indicated for:</p><p><strong><u>Adults</u></strong></p><p>&sect; Treatment of duodenal ulcers</p><p>&sect; Prevention of relapse of duodenal ulcers</p><p>&sect; Treatment of gastric ulcers</p><p>&sect; Prevention of relapse of gastric ulcers</p><p>&sect; In combination with appropriate antibiotics,&nbsp;<em>Helicobacter pylori (H. pylori)&nbsp;</em>eradication in peptic ulcer disease</p><p>&sect; Treatment of NSAID-associated gastric and duodenal ulcers</p><p>&sect; Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</p><p>&sect; Treatment of reflux esophagitis</p><p>&sect; Long-term management of patients with healed reflux esophagitis</p><p>&sect; Treatment of symptomatic gastro-esophageal reflux disease</p><p>&sect; Treatment of Zollinger-Ellison syndrome</p><p><strong><u>Paediatric use</u></strong></p><p><strong>Children over 1 year of age and &ge; 10 kg</strong></p><p>&sect; Treatment of reflux oesophagitis</p><p>&sect; Symptomatic treatment of heartburn and acid regurgitation in gastro-esophageal reflux disease</p><p><strong>Children and adolescents over 4 years of age</strong></p><p>&sect; In combination with antibiotics in treatment of duodenal ulcer caused by&nbsp;<em>H. pylori</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Adults</u></strong></p><p><strong>Treatment of duodenal ulcers</strong></p><p>The recommended dose in patients with an active duodenal ulcer is 20 mg once daily. In most patients healing occurs within two weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further two weeks treatment period. In patients with poorly responsive duodenal ulcer 40 mg once daily is recommended and healing is usually achieved within four weeks.</p><p><strong>Prevention of relapse of duodenal ulcers</strong></p><p>For the prevention of relapse of duodenal ulcer in&nbsp;<em>H. pylori&nbsp;</em>negative patients or when&nbsp;<em>H. pylori&nbsp;</em>eradication is not possible the recommended dose is 20 mg once daily. In some patients a daily dose of 10 mg may be sufficient. In case of therapy failure, the dose can be increased to 40 mg.</p><p><strong>Treatment of gastric ulcers</strong></p><p>The recommended dose is 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period. In patients with poorly responsive gastric ulcer 40 mg once daily is recommended and healing is usually achieved within eight weeks.</p><p><strong>Prevention of relapse of gastric ulcers</strong></p><p>For the prevention of relapse in patients with poorly responsive gastric ulcer the recommended dose is 20 mg once daily. If needed the dose can be increased to 40 mg once daily.</p><p><strong>H. pylori eradication in peptic ulcer disease</strong></p><p>For the eradication of&nbsp;<em>H. pylori&nbsp;</em>the selection of antibiotics should consider the individual patient&#39;s drug tolerance, and should be undertaken in accordance with national, regional and local resistance patterns and treatment guidelines.</p><p>&sect; omeprazole 20 mg + clarithromycin 500 mg + amoxicillin 1,000 mg, each twice daily for one week, or</p><p>&sect; omeprazole 20 mg + clarithromycin 250 mg (alternatively 500 mg) + metronidazole 400 mg (or 500 mg or tinidazole 500 mg), each twice daily for one week or</p><p>&sect; omeprazole 40 mg once daily with amoxicillin 500 mg and metronidazole 400 mg (or 500 mg or tinidazole 500 mg), both three times a day for one week.</p><p>In each regimen, if the patient is still&nbsp;<em>H. pylori&nbsp;</em>positive, therapy may be repeated.</p><p><strong>Treatment of NSAID-associated gastric and duodenal ulcers</strong></p><p>For the treatment of NSAID<em>-</em>associated gastric and duodenal ulcers, the recommended dose is 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period.</p><p><strong>Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk</strong></p><p>For the prevention of NSAID<em>-</em>associated gastric ulcers or duodenal ulcers in patients at risk (age&gt; 60, previous history of gastric and duodenal ulcers, previous history of upper GI bleeding) the recommended dose is 20 mg once daily.</p><p><strong>Treatment of reflux esophagitis</strong></p><p>The recommended dose is 20 mg once daily. In most patients healing occurs within four weeks. For those patients who may not be fully healed after the initial course, healing usually occurs during a further four weeks treatment period.</p><p>In patients with severe esophagitis 40 mg once daily is recommended and healing is usually achieved within eight weeks.</p><p><strong>Long-term management of patients with healed reflux esophagitis</strong></p><p>For the long-term management of patients with healed reflux esophagitis the recommended dose is 10 mg once daily. If needed, the dose can be increased to 20-40 mg once daily.</p><p><strong>Treatment of symptomatic gastro-esophageal reflux disease</strong></p><p>The recommended dose is 20 mg daily. Patients may respond adequately to 10 mg daily, and therefore individual dose adjustment should be considered.</p><p>If symptom control has not been achieved after four weeks treatment with 20 mg daily, further investigation is recommended.</p><p><strong>Treatment of Zollinger-Ellison syndrome</strong></p><p>In patients with Zollinger-Ellison syndrome the dose should be individually adjusted and treatment continued as long as clinically indicated. The recommended initial dose is 60 mg daily. All patients with severe disease and inadequate response to other therapies have been effectively controlled and more than 90% of the patients maintained on doses of 20-120 mg daily. When dose exceed 80 mg daily, the dose should be divided and given twice daily.</p><p><strong><u>Paediatric Population</u></strong></p><p>&sect; <strong><u>Children over 1 year of age and &ge; 10 kg</u></strong></p><p><strong>Treatment of reflux esophagitis</strong></p><p><strong>Symptomatic treatment of heartburn and acid regurgitation in gastro-esophageal reflux disease</strong></p><p>The posology recommendations are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:660px"><tbody><tr><td style="vertical-align:top"><p><strong>Age</strong></p></td><td style="vertical-align:top"><p><strong>Weight</strong></p></td><td style="vertical-align:top"><p><strong>Posology</strong></p></td></tr><tr><td style="vertical-align:top"><p>&ge; 1year of age</p></td><td style="vertical-align:top"><p>10-20 kg</p></td><td style="vertical-align:top"><p>10 mg once daily. The dose can be increased to 20 mg once daily if needed</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 2years of age</p></td><td style="vertical-align:top"><p>&gt; 20 kg</p></td><td style="vertical-align:top"><p>20 mg once daily. The dose can be increased to 40 mg once daily if needed</p></td></tr></tbody></table><p><strong>Reflux esophagitis:</strong> The treatment time is 4-8 weeks.</p><p><strong>Symptomatic treatment of heartburn and acid regurgitation in gastro-esophageal reflux disease:</strong>&nbsp;The treatment time is 2&ndash;4 weeks. If symptom control has not been achieved after 2&ndash;4 weeks the patient should be investigated further.</p><p>&nbsp;</p><p>&sect; <strong><u>Children and adolescents over 4 years of age</u></strong></p><p><strong>Treatment of duodenal ulcer caused by H. pylori</strong></p><p>When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents.</p><p>The treatment should be supervised by a specialist.</p><p>The posology recommendations are as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:663px"><tbody><tr><td style="vertical-align:top"><p><strong>Weight</strong></p></td><td style="vertical-align:top"><p><strong>Posology</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>15&ndash;30 kg</strong></p></td><td style="vertical-align:top"><p>Combination with two antibiotics: omeprazole 10 mg, amoxicillin 25 mg/kg body weight and clarithromycin 7.5 mg/kg body weight are all administrated together two times daily for one week.</p></td></tr><tr><td style="vertical-align:top"><p><strong>31&ndash;40 kg</strong></p></td><td style="vertical-align:top"><p>Combination with two antibiotics: omeprazole 20 mg, amoxicillin 750 mg and clarithromycin 7.5 mg/kg body weight are all administrated two times daily for one week.</p></td></tr><tr><td style="vertical-align:top"><p><strong>&gt; 40 kg</strong></p></td><td style="vertical-align:top"><p>Combination with two antibiotics: omeprazole 20 mg, amoxicillin 1 g and clarithromycin 500 mg are all administrated two times daily for one week.</p></td></tr></tbody></table><p><strong><u>Special populations</u></strong></p><p><strong>Patients with impaired renal function</strong></p><p>Dose adjustment is not needed in patients with impaired renal function (see section 5.2).</p><p><strong>Patients with impaired hepatic function</strong></p><p>In patients with impaired hepatic function a daily dose of 10&ndash;20 mg may be sufficient (see section 5.2).</p><p><strong>Older people</strong></p><p>Dose adjustment is not needed in the elderly (see section 5.2).</p><p><strong><u>Method of administration</u></strong></p><p>It is recommended to take omeprazole capsules in the morning, swallowed whole with half a glass of water. The capsules must not be chewed or crushed.</p><p><strong>For patients with swallowing difficulties and for children who can drink or swallow semi-solid food</strong></p><p>Patients can open the capsule and swallow the contents with half a glass of water or after mixing the contents in a slightly acidic fluid e.g., fruit juice or applesauce, or in non-carbonated water. Patients should be advised that the dispersion should be taken immediately (or within 30 minutes) and always be stirred just before drinking and rinsed down with half a glass of water.</p><p>Alternatively patients can suck the capsule and swallow the pellets with half a glass of water. The enteric-coated pellets must not be chewed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance, substituted benzimidazoles or to any of the excipients listed in section 6.1.
	Omeprazole like other proton pump inhibitors (PPIs) must not be used concomitantly with nelfinavir (see section 4.5).


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment may alleviate symptoms and delay diagnosis.</p><p>Co-administration of atazanavir with proton pump inhibitors is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g virus load) is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; omeprazole 20 mg should not be exceeded.</p><p>Omeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B<sub>12</sub>&nbsp;(cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B<sub>12</sub>absorption on long-term therapy.</p><p>Omeprazole is a CYP2C19 inhibitor. When starting or ending treatment with omeprazole, the potential for interactions with drugs metabolised through CYP2C19 should be considered. An interaction is observed between clopidogrel and omeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged.</p><p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like omeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><strong><u>Subacute cutaneous lupus erythematosus (SCLE)</u></strong></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping omeprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p><strong><u>Interference with laboratory tests</u></strong></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, omeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p>Some children with chronic illnesses may require long-term treatment although it is not recommended.</p><p><strong>Risek </strong>contains sucrose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella</em>&nbsp;and&nbsp;<em>Campylobacter</em>&nbsp;and, in hospitalised patients, possibly also&nbsp;<em>Clostridium difficile</em>&nbsp;(see section 5.1).</p><p>As in all long-term treatments, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Effects of omeprazole on the pharmacokinetics of other active substances</u></strong></p><p><strong><em><u>Active substances with pH dependent absorption</u></em></strong></p><p>The decreased intragastric acidity during treatment with omeprazole might increase or decrease the absorption of active substances with a gastric pH dependent absorption.</p><p><strong>Nelfinavir, atazanavir</strong></p><p>The plasma levels of nelfinavir and atazanavir are decreased in case of co-administration with omeprazole.</p><p>Concomitant administration of omeprazole with nelfinavir is contraindicated (see section 4.3). Co-administration of omeprazole (40 mg once daily) reduced mean nelfinavir exposure by ca. 40% and the mean exposure of the pharmacologically active metabolite M8 was reduced by ca. 75 &ndash;90%. The interaction may also involve CYP2C19 inhibition.</p><p>Concomitant administration of omeprazole with atazanavir is not recommended (see section 4.4). Concomitant administration of omeprazole (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a 75% decrease of the atazanavir exposure. Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg once daily) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared to atazanavir 300 mg/ritonavir 100 mg once daily.</p><p><strong>Digoxin</strong></p><p>Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10%. Digoxin toxicity has been rarely reported. However caution should be exercised when omeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should be then be reinforced.</p><p><strong>Clopidogrel</strong></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/pharmacodynamic (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and omeprazole (80 mg p.o. daily) resulting in a decreased exposure to the active metabolite of clopidogrel by an average of 46% and a decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 16%.</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of omeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, concomitant use of omeprazole and clopidogrel should be discouraged (see section 4.4).</p><p><strong>Other active substances</strong></p><p>The absorption of posaconazole, erlotinib, ketoconazole and itraconazole is significantly reduced and thus clinical efficacy may be impaired. For posaconazole and erlotinib concomitant use should be avoided.</p><p><strong><em><u>Active substances metabolised by CYP2C19</u></em></strong></p><p>Omeprazole is a moderate inhibitor of CYP2C19, the major omeprazole metabolising enzyme. Thus, the metabolism of concomitant active substances also metabolised by CYP2C19, may be decreased and the systemic exposure to these substances increased. Examples of such drugs are R-warfarin and other vitamin K antagonists, cilostazol, diazepam and phenytoin.</p><p><strong>Cilostazol</strong></p><p>Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased C<sub>max&nbsp;</sub>and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p><strong>Phenytoin</strong></p><p>Monitoring phenytoin plasma concentration is recommended during the first two weeks after initiating omeprazole treatment and, if a phenytoin dose adjustment is made, monitoring and a further dose adjustment should occur upon ending omeprazole treatment.</p><p><strong><em><u>Unknown mechanism</u></em></strong></p><p><strong>Saquinavir</strong></p><p>Concomitant administration of omeprazole with saquinavir/ritonavir resulted in increased plasma levels up to approximately 70% for saquinavir associated with good tolerability in HIV-infected patients.</p><p><strong>Tacrolimus</strong></p><p>Concomitant administration of omeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.</p><p><strong>Methotrexate</strong></p><p>When given together with proton-pump inhibitors, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of omeprazole may need to be considered.</p><p><strong><u>Effects of other active substances on the pharmacokinetics of omeprazole</u></strong></p><p><strong>Inhibitors of CYP2C19 and/or CYP3A4</strong></p><p>Since omeprazole is metabolised by CYP2C19 and CYP3A4, active substances known to inhibit CYP2C19 or CYP3A4 (such as clarithromycin and voriconazole) may lead to increased omeprazole serum levels by decreasing omeprazole&#39;s rate of metabolism. Concomitant voriconazole treatment resulted in more than doubling of the omeprazole exposure. As high doses of omeprazole have been well-tolerated adjustment of the omeprazole dose is not generally required. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p><strong>Inducers of CYP2C19 and/or CYP3A4</strong></p><p>Active substances known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St John&#39;s wort) may lead to decreased omeprazole serum levels by increasing omeprazole&#39;s rate of metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Results from three prospective epidemiological studies (more than 1000 exposed outcomes) indicate no adverse effects of omeprazole on pregnancy or on the health of the foetus/newborn child. Omeprazole can be used during pregnancy.</p><p><strong><u>Breast-feeding</u></strong></p><p>Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used.</p><p><strong><u>Fertility</u></strong></p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Omeprazole is not likely to affect the ability to drive or use machines. Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machinery.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Summary of the safety profile</u></strong></p><p>The most common side effects (1-10% of patients) are headache, abdominal pain, constipation, diarrhoea, flatulence and nausea/vomiting.</p><p><strong><u>Tabulated list of adverse reactions</u></strong></p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for omeprazole and post-marketing. None was found to be dose-related. Adverse reactions listed below are classified according to frequency and System Organ Class (SOC). Frequency categories are defined according to the following convention: Very common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100), Rare (&ge; 1/10,000 to &lt; 1/1,000), Very rare (&lt; 1/10,000), Not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:669px"><tbody><tr><td style="vertical-align:top"><p><strong>SOC/frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Hypomagnesaemia; severe hypomagnesaemia may result in hypocalcaemia.</p><p>Hypomagnesaemia may also be associated with hypokalaemia.</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Aggression, hallucinations</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Headache</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia, somnolence</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Blurred vision</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Ear and labyrinth disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting, fundic gland polyps (benign)</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dry mouth, stomatitis, gastrointestinal candidiasis</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td colspan="2" style="vertical-align:top"><p>Microscopic colitis</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Increased liver enzymes</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Alopecia, photosensitivity</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Not known:</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Malaise, peripheral oedema</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Increased sweating</p></td><td colspan="2" style="vertical-align:top">&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong><u>Paediatric population</u></strong></p><p>The safety of omeprazole has been assessed in a total of 310 children aged 0 to 16 years with acid-related disease. There are limited long-term safety data from 46 children who received maintenance therapy of omeprazole during a clinical study for severe erosive oesophagitis for up to 749 days. The adverse event profile was generally the same as for adults in short- as well as in long-term treatment. There are no long-term data regarding the effects of omeprazole treatment on puberty and growth.</p><p>&nbsp;</p><p><strong><u>To report any side effect(s): </u></strong></p><p><strong>The National Pharmacovigilance and Drug Safety Center (NPC)</strong></p><p><strong>Fax:</strong> +966-11-205-7662</p><p><strong>Call NPC at</strong> +966-11-2038222, <strong>Exts:</strong> 2317-2356-2340</p><p><strong>Reporting Hotline:</strong> 19999</p><p><strong>E-mail:</strong> npc.drug@sfda.gov.sa</p><p><strong>Website:</strong> www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited information available on the effects of overdoses of omeprazole in humans. In the literature, doses of up to 560 mg have been described, and occasional reports have been received when single oral doses have reached up to 2,400 mg omeprazole (120 times the usual recommended clinical dose). Nausea, vomiting, dizziness, abdominal pain, diarrhoea and headache have been reported. Also apathy, depression and confusion have been described in single cases.</p><p>The symptoms described have been transient, and no serious outcome has been reported. The rate of elimination was unchanged (first order kinetics) with increased doses. Treatment, if needed, is symptomatic.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>Drugs for acid-related disorders, proton pump inhibitors, ATC code: A02BC01</p><p><strong><u>Mechanism of action</u></strong></p><p>Omeprazole, a racemic mixture of two enantiomers<strong>&nbsp;</strong>reduces gastric acid secretion through a highly targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. It is rapidly acting and provides control through reversible inhibition of gastric acid secretion with once daily dosing.</p><p>Omeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the intracellular canaliculi within the parietal cell, where it inhibits the enzyme H<sup>+</sup>&nbsp;K<sup>+</sup>-ATPase - the acid pump. This effect on the final step of the gastric acid formation process is dose-dependent and provides for highly effective inhibition of both basal acid secretion and stimulated acid secretion, irrespective of stimulus.</p><p><strong><u>Pharmacodynamic effects</u></strong></p><p>All pharmacodynamic effects observed can be explained by the effect of omeprazole on acid secretion.</p><p><strong>Effect on gastric acid secretion</strong></p><p>Oral dosing with omeprazole once daily provides for rapid and effective inhibition of daytime and night-time gastric acid secretion with maximum effect being achieved within 4 days of treatment. With omeprazole 20 mg, a mean decrease of at least 80% in 24-hour intragastric acidity is then maintained in duodenal ulcer patients, with the mean decrease in peak acid output after pentagastrin stimulation being about 70% 24 hours after dosing.</p><p>Oral dosing with omeprazole 20 mg maintains an intragastric pH of &ge; 3 for a mean time of 17 hours of the 24-hour period in duodenal ulcer patients.</p><p>As a consequence of reduced acid secretion and intragastric acidity, omeprazole dose-dependently reduces/normalizes acid exposure of the oesophagus in patients with gastro-oesophageal reflux disease.</p><p>The inhibition of acid secretion is related to the area under the plasma concentration-time curve (AUC) of omeprazole and not to the actual plasma concentration at a given time.</p><p>No tachyphylaxis has been observed during treatment with omeprazole.</p><p><strong>Effect on H. pylori</strong></p><p><em>H. pylori</em>&nbsp;is associated with peptic ulcer disease, including duodenal and gastric ulcer disease.&nbsp;<em>H. pylori</em>&nbsp;is a major factor in the development of gastritis.&nbsp;<em>H. pylori</em>&nbsp;together with gastric acid are major factors in the development of peptic ulcer disease.&nbsp;<em>H. pylori</em>&nbsp;is a major factor in the development of atrophic gastritis which is associated with an increased risk of developing gastric cancer.</p><p>Eradication of&nbsp;<em>H. pylori</em>&nbsp;with omeprazole and antimicrobials is associated with, high rates of healing and long-term remission of peptic ulcers.</p><p>Dual therapies have been tested and found to be less effective than triple therapies. They could, however, be considered in cases where known hypersensitivity precludes use of any triple combination.</p><p><strong>Other effects related to acid inhibition</strong></p><p>During long-term treatment gastric glandular cysts have been reported in a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with acid-reducing drugs may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella</em>&nbsp;and&nbsp;<em>Campylobacter&nbsp;</em>and, in hospitalised patients, possibly also&nbsp;<em>Clostridium difficile.</em></p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in some patients (both children and adults) during long term treatment with omeprazole. The findings are considered to be of no clinical significance.</p><p><strong><u>Paediatric population</u></strong></p><p>In a non-controlled study in children (1 to 16 years of age) with severe reflux oesophagitis, omeprazole at doses of 0.7 to 1.4 mg/kg improved oesophagitis level in 90% of the cases and significantly reduced reflux symptoms. In a single-blind study, children aged 0&ndash;24 months with clinically diagnosed gastro-oesophageal reflux disease were treated with 0.5, 1.0 or 1.5 mg omeprazole/kg. The frequency of vomiting/regurgitation episodes decreased by 50% after 8 weeks of treatment irrespective of the dose.</p><p><strong>Eradication of H. pylori in children</strong></p><p>A randomised, double blind clinical study (H&eacute;liot study) concluded that omeprazole in combination with two antibiotics (amoxicillin and clarithromycin), was safe and effective in the treatment of&nbsp;<em>H. pylori</em>&nbsp;infection in children age 4 years old and above with gastritis:&nbsp;<em>H. pylori&nbsp;</em>eradication rate: 74.2% (23/31 patients) with omeprazole + amoxicillin + clarithromycin versus 9.4% (3/32 patients) with amoxicillin + clarithromycin. However, there was no evidence of any clinical benefit with respect to dyspeptic symptoms. This study does not support any information for children aged less than 4 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Absorption</u></strong></p><p>Omeprazole and omeprazole magnesium are acid labile and are therefore administered orally as enteric-coated granules in capsules or tablets. Absorption of omeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. Absorption of omeprazole<strong>&nbsp;</strong>takes place in the small intestine and is usually completed within 3-6 hours. Concomitant intake of food has no influence on the bioavailability. The systemic availability (bioavailability) from a single oral dose of omeprazole is approximately 40%. After repeated once-daily administration, the bioavailability increases to about 60%.</p><p><strong><u>Distribution</u></strong></p><p>The apparent volume of distribution in healthy subjects is approximately 0.3 l/kg body weight. Omeprazole is 97% plasma protein bound.</p><p><strong><u>Biotransformation</u></strong></p><p>Omeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of its metabolism is dependent on the polymorphically expressed CYP2C19, responsible for the formation of hydroxyomeprazole, the major metabolite in plasma. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of omeprazole sulfone. As a consequence of high affinity of omeprazole to CYP2C19, there is a potential for competitive inhibition and metabolic drug-drug interactions with other substrates for CYP2C19. However, due to low affinity to CYP3A4, omeprazole has no potential to inhibit the metabolism of other CYP3A4 substrates. In addition, omeprazole lacks an inhibitory effect on the main CYP enzymes.</p><p>Approximately 3% of the Caucasian population and 15-20% of Asian populations lack a functional CYP2C19 enzyme and are called poor metabolisers. In such individuals the metabolism of omeprazole is probably mainly catalysed by CYP3A4. After repeated once-daily administration of 20 mg omeprazole, the mean AUC was 5 to 10 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were also higher, by 3 to 5 times. These findings have no implications for the posology of omeprazole.</p><p><strong><u>Elimination</u></strong></p><p>The plasma elimination half-life of omeprazole is usually shorter than one hour both after single and repeated oral once-daily dosing. Omeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration. Almost 80% of an oral dose of omeprazole is excreted as metabolites in the urine, the remainder in the faeces, primarily originating from bile secretion.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Linearity/non-linearity</strong></p><p>The AUC of omeprazole increases with repeated administration. This increase is dose-dependent and results in a non-linear dose-AUC relationship after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by omeprazole and/or its metabolites (e.g. the sulfone).</p><p>No metabolite has been found to have any effect on gastric acid secretion.</p><p><strong><u>Special populations</u></strong></p><p><strong>Hepatic impairment</strong></p><p>The metabolism of omeprazole in patients with liver dysfunction is impaired, resulting in an increased AUC. Omeprazole has not shown any tendency to accumulate with once daily dosing.</p><p><strong>Renal impairment</strong></p><p>The pharmacokinetics of omeprazole, including systemic bioavailability and elimination rate, are unchanged in patients with reduced renal function.</p><p><strong>Elderly</strong></p><p>The metabolism rate of omeprazole is somewhat reduced in elderly subjects (75-79 years of age).</p><p><strong>Paediatric population</strong></p><p>During treatment with the recommended doses to children from the age of 1 year, similar plasma concentrations were obtained as compared to adults. In children younger than 6 months, clearance of omeprazole is low due to low capacity to metabolise omeprazole.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastric ECL-cell hyperplasia and carcinoids, have been observed in life-long studies in rats treated with omeprazole. These changes are the result of sustained hypergastrinaemia secondary to acid inhibition. Similar findings have been made after treatment with H<sub>2</sub>-receptor antagonists, proton pump inhibitors and after partial fundectomy. Thus, these changes are not from a direct effect of any individual active substance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellspacing="0" cellpadding="0" style="width:600px"><tbody><tr><td style="vertical-align:top"><p><strong>A.&nbsp;&nbsp;&nbsp; </strong><strong><u>Composition of Omeprazole Pellets:</u></strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Sucrose and starch neutral microgranules</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Mannitol</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Primojel</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Hydroxypropyl methyl cellulose phthalate</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Sodium lauryl sulphate</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Hypromellose</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Talc fine powder</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Methacrylic acid copolymer</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Acetone **</li></ol></td></tr><tr><td colspan="2" style="vertical-align:top"><ol><li>Ethanol 95% **</li></ol></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>B.&nbsp;&nbsp;&nbsp;&nbsp; Empty hard gelatin capsule shell ***</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>** Evaporates during manufacturing process and do not appear in the final product.</p><p>***Composition of capsule shell:&nbsp; Gelatine, Titanium Dioxide, erythrosine, brilliant blue (E133), D&amp;C yellow 10, Patent blue.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months from the date of manufacturing.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, in a dry place, protected from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>14 capsules in a white plastic bottle containing desiccants, packed in a printed carton along with a leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gulf Pharmaceutical Industries - Julphar
Digdaga, Airport Street
Ras Al Khaimah - United Arab Emirates
P.O. Box 997
Tel. No.: (9717) 2 461 461
Fax No.: (9717) 2 462 462


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20. May. 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>